Bristol-Myers Squibb Divests Imaging Agents, Considers Sale Of ConvaTec
This article was originally published in The Gray Sheet
Executive Summary
Bristol-Myers Squibb is evaluating strategic alternatives for its ConvaTec ostomy and wound care device business following the divestiture of its imaging agent franchise, announced Dec. 17
You may also be interested in...
Bristol-Myers Squibb divests ConvaTec
Drug maker Bristol divests its ostomy and wound care device business to private equity firms Nordic Capital Fund VII and Avista Capital Partners for $4.1 billion May 2. Avista previously acquired Bristol's imaging agent franchise for $525 million in December (1"The Gray Sheet" Jan. 7, 2008, p. 22). The moves are part of Bristol's broader effort to sharpen its focus on drugs
Bristol-Myers Squibb divests ConvaTec
Drug maker Bristol divests its ostomy and wound care device business to private equity firms Nordic Capital Fund VII and Avista Capital Partners for $4.1 billion May 2. Avista previously acquired Bristol's imaging agent franchise for $525 million in December (1"The Gray Sheet" Jan. 7, 2008, p. 22). The moves are part of Bristol's broader effort to sharpen its focus on drugs
Bristol-Myers Squibb Medical Imaging
Imaging agent franchise recently bought out by private equity firm Avista Capital Partners for $525 million is renamed Lantheus Medical Imaging on March 18. Based in North Billerica, Mass., Lantheus is headed by President and CEO Don Kiepert (1"The Gray Sheet" Jan. 7, 2008, p. 22)